Enterprise Value

1.353B

Cash

442.4M

Avg Qtr Burn

-33.71M

Short % of Float

7.84%

Insider Ownership

6.36%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
KER-012 (cibotercept) Details
Pulmonary hypertension, Cardiovascular disease

Phase 2

Data readout

KER-050 (elritercept) Details
Blood cancer, Cystic fibrosis, Lung disease, Myelofibrosis, Cancer

Phase 2

Data readout

KER-050 (elritercept) Details
Blood disorder, Cancer, Myelodysplastic syndrome

Phase 2

Data readout

KER-065 Details
Duchenne muscular dystrophy, Neuromuscular disease

Phase 1

Data readout

Phase 1

Data readout

KER-047 (ALK2 inhibitor) Details
Myelodysplastic syndrome, Myelofibrosis

Failed

Discontinued

KER-047 (ALK2 inhibitor) Details
Fibrodysplasia ossificans progressiva, Anemia

Failed

Discontinued